DiscoverThe Chain: Protein Engineering PodcastEpisode: 57 - The Future of Bispecific Antibody Drug Conjugates With Rakesh Dixit, Ph. D.
Episode: 57 - The Future of Bispecific Antibody Drug Conjugates With Rakesh Dixit, Ph. D.

Episode: 57 - The Future of Bispecific Antibody Drug Conjugates With Rakesh Dixit, Ph. D.

Update: 2024-01-16
Share

Description

Bispecific antibody drug conjugates (ADCs) have been undergoing a renaissance in recent years. As big pharma continues to express more interest, what can the field expect for the future of ADCs? In this episode of The Chain, Nimish Gera, Ph. D., Vice President of Biologics of Mythic Therapeutics, speaks with Rakesh Dixit, Ph. D., President & CEO of Bionavigen, about his thoughts on the future of bispecific ADCs, what to keep in mind when selecting targets, and how to choose the right payload. Dr. Dixit also shares his 35 years of experience with top biotech and pharmaceutical companies, including Merck, J&J, and AstraZeneca, and how he is using his expertise to advise companies with their drug development programs. 

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Episode: 57 - The Future of Bispecific Antibody Drug Conjugates With Rakesh Dixit, Ph. D.

Episode: 57 - The Future of Bispecific Antibody Drug Conjugates With Rakesh Dixit, Ph. D.

Cambridge Healthtech Institute